A phase II study for the safety and efficacy of TAS-102 and Bevacizumab for patients with unresectable colorectal cancer considering Oxaliplatin to stop and go. - A phase II study for the safety and efficacy of TAS-102 and Bevacizumab for patients with unresectable colorectal cancer considering Oxaliplatin to stop and go.

Gunma University0 个研究点目标入组 45 人开始时间: 2016年5月31日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. The cases with serious drug hypersensitivity or allergy. 2. Pregnant or men who expect the partner's pregnancy. 3. The cases with infectious disease requiring systemic therapy. 4. The cases with serious complications - Interstitial pneumonia, pulmonary fibrosis - Heart failure - Renal failure - Liver failure - Poor control diabetes mellitus - Poor control high blood pressure 5. Cases with ECG abnormalities are found or heart disease as a clinical problem , ( heart failure , myocardial infarction , angina pectoris). 6. Cases with gastrointestinal ulceration or bleeding. 7. Pre-existing with hemoptysis. 8. Cases with peripheral nerve disorder. 9. Patients who need a treatment for abdominal dropsy and pleural effusion. 10. Possibility of brain metastasis. 11. Perforation of the digestive tract within 6 months from the day of registration. 12. Pre-existing with thromboembolism, cerebral infarction, lung infarction and pneumonitis. 13. Surgery within 28 days from the registration day. 14. Bleeding tendency 15. Multiple primary cancers 16. Constitutional administration therapy with steroid 17. The cases judged to be unsuitable for registration. 18. Primary lesion with stricture 19. Cases with peritoneal metastasis

发起方